The first meeting of the EWGPWD in 2019 was held in Luxembourg from 18 to 20 March. The meeting was very productive and members discussed plans for the various projects and activities in which the group will be involved throughout the year and about the support which new members of the group might need to contribute to the meetings. During the second and third days of the meeting, the members of the EWGPWD and their supporters were invited to provide input on the new IMI project RADAR AD. Interested members and supporters will have the opportunity to join the RADAR-AD Patient Advisory Board. The group provided feedback on the definition and prioritisation of functional domains in Alzheimer’s disease and main features to consider when selecting a device for people with dementia. They also reviewed and provided advice on the protocol for the RADAR AD clinical trial. Five members of the RADAR-AD consortium - Irene Kanter-Schlifke (Lygature), Thanos Stavropoulos and Ioulietta Lazarou (CERTH), Nikolay Manyakov (the Janssen Pharmaceutical Companies of Johnson and Johnson) and Emilio Merlo Pich (Takeda Pharmaceuticals) joined the meeting, and together with Dianne Gove and Ana Diaz (AE) co-moderated the discussions. Jean Georges, Executive Director of AE also contributed to the meeting.
The RADAR-AD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 806999.
